Sander Flaum

Looking past COVID, the medical world is in turmoil. It’s hard enough for us in manufacturing and marketing to keep up with innovative technologies. Patients and caregivers have it especially tough since they are on the brunt end of disruptive innovations. Every day, patients face a ceaseless onslaught of sort of truths, half-truths, and flat-out lies about their healthcare, and HCPs no sooner graduate from med school than they discover much of their training is obsolete. Flaum Navigators Principal Sander A. Flaum explores how we can engage patients and physicians in the “Next Big Thing.”

Moderna COVID vaccine

Moderna Inc. completed the real-time review process needed for a full approval for the company’s Covid-19 vaccine in people aged 18 years and older.

A second-generation Covid-19 vaccine developed by CureVac and GlaxoSmithKline – designed to protect against coronavirus variants – produced a high level of immune response in a trial in rats, the companies said on May 13.

In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, researchers found when a new monoclonal antibody drug was added to treatments being given to hospitalized Covid-19 patients who were still breathing on their own, Humanigen Inc.’s lenzilumab significantly improved their odds of not needing invasive mechanical ventilation.

The world at large has become more familiar with mRNA technology due to vaccines developed against Covid-19. Now the world will be introduced to a new type of RNA-based medicine called Endless RNA, or eRNA for short.

Drugmakers on May 6 said U.S. President Joe Biden’s support for waiving patents of Covid-19 vaccines could disrupt a fragile supply chain and that rich countries should instead share more generously with the developing world.

Germany’s CureVac is on track to file for European approval of the company’s Covid-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on efficacy within closer reach. The group’s late-stage trial involves more than 37,000 volunteers in Europe and Latin America, half of whom are receiving a placebo.

Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.

The success of Covid-19 vaccines based on messenger RNA (mRNA) is smoothing the way for using the novel technology not only in other vaccines, but possibly as treatments for cystic fibrosis, cancer and other hard-to-treat diseases.

Tesla, the electric car company founded and run by Elon Musk, is building mobile molecular printers to assist Germany’s CureVac in manufacturing an experimental COVID-19 vaccine.